Susquehanna International Group
RPRX icon

Susquehanna International Group’s Royalty Pharma RPRX Stock Holding History

Susquehanna International Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Sell
25,009
-624
-2% -$32.5K ﹤0.01% 7318
2026
Q1 		$1.23M Buy
25,633
+15,542
+154% +$681K ﹤0.01% 7355
2025
Q4 		$390K Sell
10,091
-269,330
-96% -$10.3M ﹤0.01% 9349
2025
Q3 		$9.86M Sell
279,421
-159,971
-36% -$5.79M ﹤0.01% 3057
2025
Q2 		$15.8M Sell
439,392
-932,234
-68% -$30.9M ﹤0.01% 2273
2025
Q1 		$42.7M Sell
1,371,626
-698,916
-34% -$22.2M 0.01% 1121
2024
Q4 		$52.8M Buy
2,070,542
+417,680
+25% +$11.1M 0.01% 1076
2024
Q3 		$46.8M Buy
1,652,862
+157,504
+11% +$4.36M 0.01% 1148
2024
Q2 		$39.4M Buy
1,495,358
+1,063,108
+246% +$29.5M 0.01% 1145
2024
Q1 		$13.1M Buy
432,250
+1,617
+0.4% +$47.7K ﹤0.01% 2256
2023
Q4 		$12.1M Sell
430,633
-110,814
-20% -$3.05M ﹤0.01% 2397
2023
Q3 		$14.7M Buy
541,447
+156,708
+41% +$4.65M ﹤0.01% 2091
2023
Q2 		$11.8M Buy
384,739
+139,703
+57% +$4.73M ﹤0.01% 2309
2023
Q1 		$8.83M Buy
245,036
+70,106
+40% +$2.6M ﹤0.01% 2625
2022
Q4 		$6.91M Buy
+174,930
New +$7.3M ﹤0.01% 2753
2022
Q1 		– Sell
-6,996
Closed -$275K – 13836
2021
Q4 		$279K Buy
+6,996
New +$272K ﹤0.01% 10662
2021
Q3 		– Sell
-32,027
Closed -$1.24M – 13438
2021
Q2 		$1.31M Sell
32,027
-198,593
-86% -$8.45M ﹤0.01% 7006
2021
Q1 		$10.1M Buy
230,620
+220,467
+2,171% +$10.5M ﹤0.01% 2757
2020
Q4 		$508K Sell
10,153
-73,955
-88% -$3.14M ﹤0.01% 8257
2020
Q3 		$3.54M Buy
84,108
+46,895
+126% +$2.01M ﹤0.01% 3588
2020
Q2 		$1.81M Buy
+37,213
New +$1.84M ﹤0.01% 4682

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group's RPRX Position: Q2 2026 in Review

Susquehanna International Group reduced its Royalty Pharma (RPRX) stake by 2.4% in Q2 2026, selling an estimated $32.5K and leaving 25,009 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #7318.

Susquehanna International Group first reported a position in RPRX in Q2 2020 and has held it in 21 quarters since. The position peaked at $52.8M in Q4 2024. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Susquehanna International Group held 25,009 shares of Royalty Pharma worth $1.4M as of Q2 2026.
  • Susquehanna International Group sold 624 Royalty Pharma shares in Q2 2026, an estimated $32.5K.
  • Royalty Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #7318 holding.
  • Susquehanna International Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 21 quarters since.
  • Susquehanna International Group's Royalty Pharma position peaked at $52.8M in Q4 2024.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.